The Global
Cancer Biomarkers Market is set to witness a growth rate of
6-7% by 2026.Growing use of cancer biomarkers in drug discovery and
development, favorable funding related to cancer biomarkers, growing research
on cancer biomarkers, technological advancements in the development of cancer
biomarkers, and an increasing burden of cancer are some of the key factors
driving the market growth.
Cancer biomarkers are biological molecules that indicate the
presence of cancer in a patient. They are produced either by the cancer cells
or by noncancer cells in response to cancer.
Download a free sample report now
👉
https://meditechinsights.com/cancer-biomarkers-market/request-sample/
Use of Cancer Biomarkers Across Different Stages of
Cancer Fuels Its Demand
Cancer biomarkers play a critical role in accurately
evaluating and managing cancer in different stages. They are used for cancer
risk assessment, screening, differential diagnosis, prognosis determination,
treatment response prediction, pharmacokinetics/predicting drug doses, and
monitoring treatment response. Clinical use of biomarkers for various types of
cancer - breast cancer, prostate cancer, ovarian cancer, pancreatic cancer,
colon cancer germ cell cancer, and thyroid cancer, amongst others drives its
demand.
Growing Prominence of Cancer Biomarkers in Drug
Discovery, Development, and Approval Processes
Biomarkers are increasingly being used at every stage of
drug discovery and development. The utilization of biomarkers makes the drug
discovery, development, and approval processes more efficient. For the
successful treatment of complex chronic diseases (such as cancer), to develop
precision medicine and targeted therapies, it is critical to monitor the
molecular basis of disease initiation and progression before, during, and after
the therapeutic intervention. The need to better understand the factors affecting
response to drugs has led to an increased demand for additional efficacy,
specificity, and safety testing of drugs during new drug development which in
turn has bolstered the demand for cancer biomarkers.
Favorable Funding Environment Set to Drive the Cancer
Biomarkers Market Growth
To alleviate the burden of cancer, organizations across the
globe are offering funding/grants to discover cancer biomarkers that can treat
diseases with unmet needs. For instance,
- Cancer
Research UK is offering to fund researchers interested in ‘Biomarker
Research’. Through their funding scheme ‘Biomarker Project Awards’, Cancer
Research UK is offering 3-year funding of up to £100,000 per year for
biomarker assay development, validation, and qualification where there is
a clear line of sight to clinical implementation
- Similarly,
the National Institutes of Health (NIH) - Cancer Biomarkers Research Group
is offering several funding opportunities for cancer biomarkers
- In
2021, Wayne State University researchers received Department of Defense
(DoD) funding for the prostate cancer biomarker discovery project. The
three-year project received $863,222 as a DoD Idea Development Award.
- In
2018, Fred Hutchinson Cancer Research Center biostatistician Dr. James Dai
was recently awarded a $2.1 million grant from the National Cancer
Institute for cancer biomarker research
- In
2018, The US National Cancer Institute awarded $6.5 million in funding
(over seven years) to Professor Arul Chinnaiyan, from the University of
Michigan to identify cancer biomarkers to improve diagnosis and develop
new targeted therapies
- In
2018, the National Institutes of Health (NIH) awarded a $6.4 million grant
to Albert Einstein College of Medicine and Hackensack University Medical
Center for breast cancer biomarker research
“Cancer biomarker testing is revolutionizing cancer
treatment for several types of tumors. The moment we identify a key biomarker
and figure out what is driving tumor growth, we can develop treatment
strategies that particularly target the tumor abnormality and eventually
improve patient outcomes.” - Director, Leading Cancer Center,
United States
Organic and Inorganic Growth Strategies Adopted by
Players to Establish Their Foothold in Cancer Biomarkers Market
The cancer biomarkers market is an emerging market marked by
the presence of both established and new players. Players operating in the
market adopt both organic and inorganic growth strategies such as new
product/program launches, partnerships, and acquisitions to garner market
share. For instance,
- In
March 2022, Vela Diagnostics launched new panels to detect cancer
biomarkers
- In
March 2022, SYNLAB partnered with OncoDNA to provide comprehensive
biomarker testing for cancer therapy selection in Germany
- In
February 2022, OncoDNA launched the OncoDEEP Kit for comprehensive
biomarker testing of solid tumors
- In
May 2021, GE Healthcare acquired oncology biomarker maker Zionexa. GE
Healthcare will develop and commercialize the Zionexa biomarkers and PET
imaging agent, Cerianna
- In
April 2021, The Cancer Support Community (CSC) launched a new biomarker
testing tool for lung cancer patients. The online tool empowers lung
cancer patients and caregivers in the treatment decision-making process
- In
April 2021, Amgen launched Biomarker Assist, a program to help more
patients with metastatic (stage IV) non-small cell lung cancer (NSCLC)
gain access to biomarker testing
Future Outlook: Global Cancer Biomarkers Market
The global cancer biomarkers market is a promising market
that is expected to gain further momentum in the coming years due to
technological advancements in genomic and proteomic technologies (gene array
technology, improved two-dimensional gel electrophoresis, new mass
spectrometric techniques) and bioinformatic tools that showcase the potential
to meet the growing demand for new biomarkers that are both sensitive and
specific.
To ensure precise evaluation and better clinical cancer
management, the demand for prognostic and predictive cancer biomarkers is
expected to increase. With the growing development of new treatments, there is
a growing requirement for biomarkers that can predict outcomes and direct
patients/providers on which treatment options are most likely to be effective
for a particular patient with a particular tumor.
Download a sample report for
in-depth competitive insights
https://meditechinsights.com/cancer-biomarkers-market/request-sample/
Competitive Landscape Analysis: Cancer Biomarkers Market
The Cancer Biomarkers Market is marked by the presence of
prominent players such as Roche, Thermo Fisher Scientific, QIAGEN, Illumina,
Bio-Rad Laboratories, Abbott Laboratories, Sysmex, and others. The foray of
players such as R&D Systems, BioVision, Olink, Meso Scale Diagnostics, and
others are changing the dynamics of the Cancer Biomarkers market and have made
the market more competitive.
Medi-Tech Insights
is a healthcare-focused business research & insights firm. Our clients
include Fortune 500 companies, blue-chip investors & hyper-growth
start-ups. We have completed 100+ projects in Digital Health, Healthcare IT,
Medical Technology, Medical Devices & Pharma Services in the areas of
market assessments, due diligence, competitive intelligence, market sizing and
forecasting, pricing analysis & go-to-market strategy. Our methodology
includes rigorous secondary research combined with deep-dive interviews with
industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment